º«¹úÂãÎè

MSSI newsletter

News

Six principal investigators from The Neuro receive CIHR grants

Published: 10 February 2025

Projects include important research on P²¹°ù°ì¾±²Ô²õ´Ç²Ô’s, glioblastoma and dementia

Ìý

The projects of six principal investigators at The Neuro will get major boosts thanks to the latest round of grants from the Canadian Institutes of Health Research (CIHR). More than $6 million in total will fund important research into several neurological disease areas. The studies represent more than a quarter of the º«¹úÂãÎè projects supported by CIHR in this round of funding. Neuro researchers are co-investigators on two other CIHR-funded projects.Ìý

Ìý

Xiaoqian ChaiÌý

Title: “Precision multi-modal brain imaging of high-level cognitive functional network development in autism via ultra-high field MRIâ€Ìý

Funding amount: $703,800Ìý

Description: This project aims to elucidate how brain network organization differences are associated with behavioral symptoms in children with autism, using a novel individualized approach that combines multimodal precision neuroimaging, ultra-high field magnetic resonance imaging (MRI) and naturalistic movie paradigms. In particular, it will investigate the organization of the brain networks that underlie social inferencing, language and memory functions.Ìý

Ìý

Alain DagherÌý

Title: Effects of GLP1-agonist induced weight loss on brain, metabolic, and cerebrovascular health measuresÌý

Funding amount: $1,346,400Ìý

Description: Obesity in mid-life is a significant risk factor for dementia and Alzheimer's disease. However until recently there were very few safe and effective weight loss treatments available. This situation has changed in the last few years with the advent of a class of medications called GLP1 agonists, which can cause significant weight loss. This project will recruit 120 individuals aged 30-55 and administer a medication called tirzepatide to them for one year. It will then use magnetic resonance imaging to see if weight loss is associated with changes in brain health.ÌýÌý

Ìý

´³Ã©°ùô³¾±ð FortinÌý

Title: Characterizing and improving new treatments for IDH-mutant diffuse gliomasÌý

Funding amount: $1,051,875Ìý

Description: In one type of brain cancer the tumors have a mutation in the IDH1 gene. Remarkably, patients treated with drugs that inhibit the IDH mutation have slower tumor progression and wait longer before needing additional treatment. While this offers hope in some patients, IDH inhibitors don't work for all patients. The goal of this research is to find ways to make IDH inhibitors produce better responses in a larger number of patients. It will do this by using new innovative disease models and by studying tumors from patients treated with IDH inhibitors. Overall, the study will help develop better treatments for patients with IDH-mutant gliomas.Ìý

Ìý

Austen MilnerwoodÌý

Title: LRRK2 mutant mechanisms & targeting for PDÌý

Funding amount: $1,067,175Ìý

Description: This research investigates the early dysfunction in brain circuits associated with Parkinson's disease (PD), particularly in relation to mutations in the LRRK2 and VPS35 proteins. These mutations cause early alterations in brain activity, which can potentially be reversed with LRRK2 inhibitors. The study examines how LRRK2 inhibition affects animal models, to determine if early intervention can prevent disease progression. The findings aim to inform clinical trials, offering insights into the safety and efficacy of LRRK2 inhibitors and their potential application to different PD types, contributing to the development of novel treatments.Ìý

Ìý

Adrien Peyrache Ìý

Title: How dysfunction of hippocampal sharp wave-ripples leads to cognitive impairment in a mouse model of Christianson syndromeÌý

Funding amount: $914,175Ìý

Description: Sleep plays an important role in the formation of memories. Losing sleep, even for a few hours, can have an unfavourable effect on remembering. Intriguingly, comorbidities of sleep disturbances and cognitive decline have been associated with many neurological disorders and ageing. In previous studies, the scientists found that patients with Christianson syndrome, a complex brain disorder, often experience sleep disturbances. Interestingly, those with more severe sleep issues tend to have more behavioral and emotional problems during the day. Christianson syndrome is caused by loss-of-function mutations in a gene encoding a specific protein known as NHE6. In this grant, they build on their previous published work and extensive preliminary data to study how lack of NHE6 leads to disturbances in neuronal activity and memory.ÌýÌý

Ìý

Jean-Baptiste PolineÌý

Title: Characterizing and predicting PD biological stages with neuroimaging across global populationsÌý

Funding amount: $1,051,875Ìý

Description: Recently, P²¹°ù°ì¾±²Ô²õ´Ç²Ô’s research has been going through a paradigm shift towards defining objective biological staging criteria to complement or replace symptom driven detection and progression tracking. This new framework provides a new opportunity for discovery of non-invasive biomarkers for predicting disease progression. The scientists aim to leverage this staging framework to characterize the regions of the brain that characterize PD patients at different disease stages. We assess the utility of these brain signatures as biomarkers by their prognostic ability to predict future patient stages across multiple longitudinal datasets. To this aim, we will develop a distributed data management and processing framework, then use this infrastructure to characterize specifically brain network level signatures to study and predict disease progression.Ìý

Back to top